Evidence map›Paper›PMID 35919923›Full record

ArticleAfrican journal of thoracic and critical care medicine2022

Position statement on endoscopic lung volume reduction in South Africa: 2022 update.

C F N Koegelenberg, R N van Zyl-Smit, K Dheda, B W Allwood, M J Vorster, D Plekker, D-J Slebos, K Klooster, P L Shah, F J F Herth and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in African journal of thoracic and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

C F N KoegelenbergDivision of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.
R N van Zyl-SmitDivision of Pulmonology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-5563-8429
K DhedaPanorama Heart and Lung Unit, Panorama Mediclinic, Cape Town, South Africa.
B W AllwoodDivision of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.
M J VorsterPanorama Heart and Lung Unit, Panorama Mediclinic, Cape Town, South Africa.
D PlekkerKuils River Hospital, Cape Town, South Africa.
D-J SlebosDepartment of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
K KloosterDepartment of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
P L ShahRoyal Brompton, Harefield NHS Foundation Trust, and National Heart & Lung Institute, Imperial College, London, United Kingdom.
F J F HerthPulmonology and Critical Care Medicine, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany.
Assembly on Interventional Pulmonology of the South African Thoracic Society
Stellenbosch University · ZAUniversity of Groningen · NLGroote Schuur Hospital · ZAHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) remains one of the most common causes of morbidity and mortality in South Africa. Endoscopic lung volume reduction (ELVR) was first proposed by the South African Thoracic Society (SATS) for the treatment of advanced emphysema in 2015. Since the original statement was published, there has been a growing body of evidence that a certain well-defined sub-group of patients with advanced emphysema may benefit from ELVR, to the point where the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines and the United Kingdom National Institute for Health and Care Excellence (NICE) advocate the use of endoscopic valves based on level A evidence. Patients aged 40 - 75 years with severe dyspnoea (COPD Assessment Test score ≥10) despite maximal medical therapy and pulmonary rehabilitation, with forced expiratory volume in one second (FEV

Indexed as

Coilsemphysemaendoscopic lung volume reductionvalves

Identifiers

PMID35919923
PMCPMC9315962
OpenAlexW4289787203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.